# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/31221870

# data[].attributes.body
https://care.diabetesjournals.org/content/25/7/1159.short

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608673/

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/28526671

# data[].attributes.body
https://www.researchgate.net/profile/K_M_V_Narayan/publication/12043457_Effectiveness_of_self-management_training_in_type_2_diabetes_A_systematic_review_of_randomised_controlled_trials_Norris_SL_Engelgau_MM_Venkat_Narayan_KM_Diabetes_Care_2001_24_3_561_587_11289485/links/541abc1f0cf25ebee988bd55.pdf

# data[].attributes.body
https://science.sciencemag.org/content/271/5256/1734.long

https://www.pnas.org/content/99/19/12293.long

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231274/

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/16730267

https://science.sciencemag.org/content/271/5256/1734.long

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/20525992?dopt=Abstract

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/28194802

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/29529356

https://www.ncbi.nlm.nih.gov/pubmed/28435269
Biofilms!
https://www.ncbi.nlm.nih.gov/pubmed/27735846

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443571/

# data[].attributes.body
https://synapse.koreamed.org/DOIx.php?id=10.3349/ymj.2010.51.6.932&vmode=FULL

https://www.sciencedirect.com/science/article/pii/S0091674997800371
https://www.sciencedirect.com/science/article/pii/S0385814609001370

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458621/

# data[].attributes.body
https://cvi.asm.org/content/cdli/17/4/513.full.pdf

# data[].attributes.body
https://mbio.asm.org/content/9/5/e01777-18.long

# data[].attributes.body
https://pubs.acs.org/doi/10.1021/acs.jproteome.5b00697

# data[].attributes.attachment_link.title
Intramolecular Interactions Dominate the Autoregulation of Escherichia coli Stringent Factor RelA.

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/31331436

# data[].attributes.headline
Methods to measure intercellular bacterial growth!

# data[].attributes.subject
Methods to measure intercellular bacterial growth!

# data[].attributes.body
https://link.springer.com/protocol/10.1007/978-1-59745-570-1_26

https://www.nature.com/articles/nature06345

# data[].attributes.body
Bc

# data[].attributes.attachment_link.title
Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/31581314

# data[].attributes.body
https://www.sciencedirect.com/science/article/pii/S0002929707638488

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1801337/

# data[].attributes.attachment_link.readable_text
RATIONALE:

Pancreatic cancer (PC) is considered as one of the deadliest cancers all over the world. Germline and somatic BRCA1/2 mutations have been widely studied in breast and ovarian carcinomas as they have been found to enhance the risk for disease progression. Olaparib, an oral poly(adenosine diphosphate-ribose)polymerase (PARP) inhibitor, has been approved for the treatment strategy of ovarian cancer with any BRCA1/2 mutations. There is a lack of studies which focus on the treatment of other cancer with BRCA-Mutation.

PATIENT CONCERNS:

This report describes a patient whose presenting complaints were "Physical examination showed that the pancreas was occupied for one month." He initially was diagnosed with stage IV PC based on conventional imaging and pathologic assessment. He had a known germline BRCA 2 mutation, which exhibited a good response to PARP inhibitor therapy.

DIAGNOSIS:

Through the biopsy histopathological examination, imaging examination, and genetic testing, the patient was diagnosed as metastatic PC with BRCA2 mutation.

INTERVENTIONS:

He received gemcitabine and albumin-bound paclitaxel chemotherapy from March 15, 2017 to June 30, 2017, and Nivolumab immunotherapy as the maintenance therapy. After serum CA-199 level increased, Olaparib was orally administered from August 17, 2017 to March. After tumor relapsed, he received multiple lines of chemotherapy, including Trametinib Oxaliplatin, S-1, bevacizumab, and irinotecan liposome injection till July 17, 2018.

OUTCOMES:

We observed the patient had a good progression-free survival (7.4 months); the lesion of the pancreas was classified as partial disease through Olaparib treatment, which indicated significant shrinkage. But it is difficult to conclude whether such therapy could help prolong the overall survival for such patients.

LESSONS:

The targeted therapy Olaparib showed early signs of potential in treating PC in patients with mutations of the BRCA genes. With emerging therapeutic modalities and next-generation sequencing development, it is increasingly relevant to consider mutation screenings of patients with PC.

# data[].attributes.attachment_link.keywords[]
national center for biotechnology information

# data[].attributes.attachment_link.keywords[]
united states national library of medicine

# data[].attributes.attachment_link.title
A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.

# data[].attributes.attachment_link.description
RATIONALE: Pancreatic cancer (PC) is considered as one of the deadliest cancers all over the world. Germline and somatic BRCA1/2 mutations have been widely studied in breast and ovarian carcinomas as they have been found to enhance the risk for disease progression.

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/21718651

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315560/

# data[].attributes.attachment_link.readable_text
1

Department of Radiology, Breast Imaging, Hospices Civils de Lyon, Centre Hospitalier Femme Mère Enfant, 59 Boulevard Pinel, 69677 Bron, France.

2

Department of Radiology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.

# data[].attributes.attachment_link.keywords[]
national center for biotechnology information

# data[].attributes.attachment_link.keywords[]
united states national library of medicine

# data[].attributes.attachment_link.title
Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.

# data[].attributes.attachment_link.description
1 Department of Radiology, Breast Imaging, Hospices Civils de Lyon, Centre Hospitalier Femme Mère Enfant, 59 Boulevard Pinel, 69677 Bron, France. 2 Department of Radiology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/31575654

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/16546294

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/31356717

# data[].attributes.body
https://www.sciencedirect.com/science/article/pii/S0195666316304664?via%3Dihub

# data[].attributes.attachment_link.title
The sweet life: The effect of mindful chocolate consumption on mood.

# data[].attributes.attachment_link.description
Appetite. 2017 Jan 1;108:21-27. doi: 10.1016/j.appet.2016.09.018. Epub 2016 Sep 15. Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

# data[].attributes.body
https://www.ncbi.nlm.nih.gov/pubmed/27642035

http://misc.karger.com/gazette/68/morristaren/art_3.htm

https://www.nature.com/articles/1602707

# data[].attributes.body
not all aricles are free
keywords are not quality
broad

# data[].attributes.body
Easy quick links to other information/ pages

purely science

diverse
free to use